A Pharmaceutical entity from India is looking for strategic investment opportunities in API and Formulation entities in India.
TARGET BRIEF
A pharmaceutical client is looking out for acquiring a GMP / MHRA approved/certified Formulation plant having a capacity of approx 200-250 MT per month and an API plant having capacity of producing volume building API’s ( paracetamol, ibuprofen, Metformin) of around 300 – 500 MT per month anywhere in India. The firm has established world-class manufacturing facilities by leveraging state-of-the-art technology, incorporating best practices and adhering to stringent regulatory compliance. The Plants are approved by prestigious US FDA, UK MHRA, Australian TGA and other foreign health authorities. R&D capabilities include dossier development, chemical synthesis, process optimization, formulation development, analytical development.
Proposal
Industry
Pharmaceuticals
Sub Industry
Integrated
Deal Size
INR 100 - 200 Cr
Funding Sources
Cash,Fresh Debt
Synergies Sought
Manufacturing Strengths (Production/Operations)
Deal Option
Complete Buyout
Open For Distressed Assets
Target Location
12, 9, 14, 15, 33, 16, 1, 17, 6, 4, 18, 19, 20, 10, 21, 7, 2, 22, 23, 24, 25, 26, 5, 3, 31, 30, 29, 28, 13, 8, 27
Type
General & Beta Lactum
Product
paracetamol, ibuprofen, Metformin
Export
Yes
Formulation Type
Oral Solids, Liquids, Parenteral
Type
Branded
Therapeutic Area
Chronic, Acute
Business Operation Information
Industry
Pharmaceuticals
Sub-Industry
Bulk Drug manufacturing
Division
Division`s Buyers/Customers
Business Documents
Recommended Deals
Acquisition opportunity: Agricultural chemicals company is looking to acquire an...
The target should be engaged in API business. Preferable product portfolio incl...
₹ 600 - 700 Cr
A Pharmaceuticals (Contract Research & Manufacturing Services (CRAMS)) entity fr...
The Company is seeking acquisition targets in the CRO and/or CDMO space with the...